Molbio Diagnostics IPO Day 3: Subscription Status, Timeline & Key Issue Details

The ₹939.70 crore Molbio Diagnostics initial public offering (IPO) entered its final day of public subscription today, August 12, 2026, with a price band of ₹768 to ₹807 per share. As of 10:45 AM on day 3, the issue had been subscribed 4.87 times.

The IPO will remain open for subscription until August 12, 2026. The basis of allotment is expected to be finalised on August 13, 2026, while the shares are tentatively scheduled to be listed on the NSE and BSE on August 17, 2026.

Molbio Diagnostics IPO - Issue Details

• Issue Type: Book Built Issue (Fresh Issue + OFS)
• Total Issue Size: Up to ₹939.70 crore
• Fresh Issue: Up to ₹200.00 crore
• Offer for Sale (OFS): Up to 739.70 crore 
• Face Value: ₹1 per equity share
• Price Band: To be announced
• Lot Size: To be announced
• Minimum Investment Amount (Retail Investor): ₹14,526 (18 shares at the upper price)
• Listing: BSE, NSE
• Book Running Lead Managers: Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited, Jefferies India Private Limited and Motilal Oswal Investment Advisors Limited
• Registrar: KFin Technologies Limited

Molbio Diagnostics IPO Timeline (Tentative)

The expected IPO schedule is as follows:

Note: The allotment and listing dates are tentative and may be revised.

Utilisation of IPO Proceeds

The company intends to utilise the net proceeds from the fresh issue towards:

• Funding capital expenditure for setting up infrastructure for a research and development facility and Centre of Excellence to be operated by the wholly owned subsidiary, Bigtec, along with office space for the company, its subsidiaries and associates.
• Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit
• General corporate purposes

Molbio Diagnostics IPO Day 3 Subscription Status

[August 12, 2026, 10:45 A.M.]

About Molbio Diagnostics Limited

Founded in 2000, Molbio Diagnostics Limited develops point-of-care (POC) diagnostic solutions designed to make molecular testing faster and more accessible for infectious and non-communicable diseases. Its flagship Truenat platform is a portable, battery-operated PCR system suited for resource-constrained settings and capable of delivering test results in around an hour. As of March 31, 2026, the company offered 43 assays covering 30 diseases, including tuberculosis (TB), COVID-19, HIV, hepatitis B and C, and HPV.

Beyond molecular diagnostics, Molbio also operates in radiology, digital pathology and breast health screening through its subsidiaries and strategic partnerships. Its Truenat technology is protected by patents in more than 100 countries. The company’s tuberculosis test is among the rapid molecular diagnostic tests recommended by the World Health Organization (WHO) for the initial detection of TB and rifampicin resistance.

Key Financial Highlights 

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.  

To read the RA disclaimer, please click here